Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Abstract

Sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients with <i>BRAFV600</i>-mutant melanoma.